Characterizing the Crosstalk of NCAPG with Tumor Microenvironment and Tumor Stemness in Stomach Adenocarcinoma by Zheng Xiang, Genlan Cha, Yihao Wang, Jikai Gao, Jianguang Jia

“…An immune risk scoring model related to NCAPG expression and immune score was constructed which showed a favorable performance in predicting STAD prognosis as well as predicting the response to immunotherapy. In addition, we found a higher mRNA stemness index (mRNAsi) in the high-risk group and a positive correlation between NCAPG expression and mRNAsi. …”
Get full text

Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project by Toni Maria Janke, Laura Moysig, Christine Blome, Katharina C. Kähler

“…Abstract Purpose Targeted treatment and immunotherapy, both adjuvant treatment options, come with a certain toxicity and can cause severe side effects. …”
Get full text

Leptospira and Inflammation by C. F. Gonçalves-de-Albuquerque, P. Burth, A. R. Silva, M. Younes-Ibrahim, H. C. Castro-Faria-Neto, M. V. Castro-Faria

“…This paper will discuss both the role of immunogenic and pathogenic molecules during leptospirosis infection and possible new targets for immunotherapy against leptospira components. Leptospira, possess a wide variety of mechanisms that allow them to evade the host immune system and cause infection. …”
Get full text

Identification of KIFC1 as an independent prognostic marker in renal clear cell carcinoma correlates with tumor proliferation and immune infiltration by Bin Du, Jia Wang, Jinping Zheng, Jing Huo, Pu Wang

“…High expression of KIFC1 may predict a poor immunotherapy outcome. By proteomics, we analyzed proteins interacting with KIFC1; spliceosome proteins had the most significant enrichment, indicating the new directions for KIFC1 investigation. …”
Get full text

Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells by Hidehito Saito, Keisuke Okita, Noemi Fusaki, Michael S. Sabel, Alfred E. Chang, Fumito Ito

“…The ability to reprogram TILs containing patient-specific tumor-reactive repertoire might allow the generation of patient- and tumor-specific polyclonal T cells for cancer immunotherapy.…”
Get full text

Comprehensive analysis reveals the tumor suppressor role of macrophage signature gene FCER1G in hepatocellular carcinoma by Deyu Kong, Yiping Zhang, Linxin Jiang, Nana Long, Chengcheng Wang, Min Qiu

“…Our prognostic model provides new insights into precision and immunotherapy for HCC and holds significant implications for future clinical applications.…”
Get full text

Acute Hepatitis Induced by Intravesical BCG Therapy: A Rare but Serious Complication by Hakima Abid, Mouna Figuigui, Sidi Adil Ibrahimi, Mohamed El Abkari, Mohamed Mzyiene, Soufiane Ennaciri, Ouima Justin Ziba, Mohamed Jamal El Fassi, Layla Tahiri Elousrouti, Laila Chbani

“…Bacillus Calmette and Guérin (BCG), widely used as a vaccination to prevent tuberculosis, is also used as immunotherapy, by intrabladder instillation, to treat superficial bladder cancers and prevent recurrence. …”
Get full text

Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma by Ying Ni, Qun Zhang, Xiaochen Tang, Xiuchun Li, Shiguang Ye, Yan Lu, Aibin Liang, Ping Li

“…In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. …”
Get full text

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion by Yang Xia, Chunye Huang, Min Zhong, Hongguang Zhong, Ruiwen Ruan, Jianping Xiong, Yangyang Yao, Jing Zhou, Jun Deng

“…The review thoroughly examines both clinical and practical evidence regarding the use of c-MET inhibitors alongside PD-1/PD-L1 inhibitors, emphasizing that focusing on c-MET with immunotherapy enhances the effectiveness of treating MET tumors exhibiting elevated PD-L1 expression.…”
Get full text

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC by Masayuki Shirasawa, Tatsuya Yoshida, Takaji Matsutani, Yuki Takeyasu, Naoko Goto, Shigehiro Yagishita, Shigehisa Kitano, Hiroaki Kuroda, Toyoaki Hida, Takayasu Kurata, Yuichiro Ohe

Get full text

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer by Qichen Zhang, Xiaojuan Han, Jiayi Liu, Hui Qiao

“…Adverse effects were comparable between the groups in terms of thyroid function (p = 0.898), but bone marrow suppression and gastrointestinal reactions were significantly less severe in the PD‐L1 group (p = 0.047 and p = 0.002). Conclusion Immunotherapy combined with chemotherapy offers significant benefits for advanced SCLC patients, irrespective of the type of inhibitor used. …”
Get full text

Hijacking of the nervous system in cancer: mechanism and therapeutic targets by Yu Zhang, Qili Liao, Xuyang Wen, Jiayan Fan, Tifei Yuan, Xuemei Tong, Renbing Jia, Peiwei Chai, Xianqun Fan

“…Importantly, neural activity is also implicated in modulating the efficacy of therapeutic interventions, including immunotherapy. On the contrary, the nervous system potentially has a suppressive effect on tumorigenesis, further underscoring a dual-edged role of neurons in cancer progression. …”
Get full text

The magnitude of exercise‐induced progenitor cell mobilisation and extravasation is positively associated with cardiorespiratory fitness by Mark Ross, Sarah Aldred, Mark T. Drayson, Jos A. Bosch, James E. Turner

Get full text

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma by Youjia Li, Kai Qu, Xiuli Li, Xin Yang, Kanghuai Zhang, Jiao Xie

“…Recognizing the limitations of current understanding, there is a clear call for further research, particularly on identifying biomarkers that may predict adverse reactions to immunotherapy, to guide precision medicine and improve patient safety.…”
Get full text

Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Pros... by Marlena Janiczek, Łukasz Szylberg, Paulina Antosik, Anna Kasperska, Andrzej Marszałek

“…A study on IL-17 may become a starting point for further research on an attempt to use, for example, immunotherapy in PCa.…”
Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

“…Given the increasing diversity and complexity of cancer immunotherapy, it is essential to vigilantly screen for thyroid irAEs.…”
Get full text

Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients by Zhaoyue Yan, Yushuai Gao, Jinliang Yu, Zhiyuan Shen, Xingyao Bu

“…Moreover, the high-risk group had a greater immune infiltration and was most likely to benefit from immunotherapy. Gene set enrichment analysis suggested that immune and oncogenic pathways were enriched in high-risk glioma patients. …”
Get full text

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma by Zhuning Wang, Junqiao Yao, Tengyu Dong, Xing Niu

“…High-risk subset displayed higher somatic mutations, CNVs, TMB, SNV neoantigens, aneuploidy score, CTA score, homologous recombination defects, and intratumor heterogeneity, cytolytic activity, CD8+ T effector, and antigen processing machinery, proving that this subset might benefit from immunotherapy. Increased stemness indexes and activity of oncogenic pathways might contribute to undesirable prognostic outcomes for high-risk subset. …”
Get full text

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer. by Yinghao He, Fuqiang Liu, Qingshu Li, Zheng Jiang

“…In summary, our study provides a relatively accurate prognostic tool for colon cancer patients, offering guidance for treatment selection and indicating the potential of immunotherapy in colon cancer.…”
Get full text

Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB by Bai Y, Wang X, Wang B

“…We confirmed that PDGFB positively correlated with CD8 and PDL1 expression in lower grade glioma.Conclusion: This study concludes that PDGFB may serve as a potential prognostic marker and a potential targetable pathway in cancer immunotherapy. Overall, the study sheds new light on the role of PDGFB in cancer and highlights its potential clinical significance.Keywords: PDGFB, pan-cancer, prognosis, immune cell infiltration, biomarker…”
Get full text